Biodesix, Inc. (BDSX)
| Market Cap | 387.30M |
| Revenue (ttm) | 45.56M |
| Net Income (ttm) | -31.35M |
| Shares Out | 26.86M |
| EPS (ttm) | -6.48 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $14.24 |
| Previous Close | $14.12 |
| Change ($) | 0.12 |
| Change (%) | 0.85% |
| Day's Open | 14.12 |
| Day's Range | 13.78 - 15.00 |
| Day's Volume | 65,043 |
| 52-Week Range | 10.85 - 31.99 |
BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, has announced their plan to add ...
BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced in partnership w...
BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will rel...
BOULDER, Colo.--(BUSINESS WIRE)-- #patientsfirst--Pulmonary disease expert, Dr. Susan Garwood, is hosted by CHEST to discuss standardized risk assessment to inform lung nodule management
BOULDER, Colo.--(BUSINESS WIRE)-- #patientsfirst--Biodesix releases new data at AACR annual meeting on the use of proteomic profiling to help guide physician treatment strategies for NSCLC patients.
BOULDER, Colo.--(BUSINESS WIRE)-- #patientsfirst--Biodesix receives two important U.S. patents for diagnostic methods, which seek to improve care for cancer patients.
BOULDER, Colo.--(BUSINESS WIRE)--Biodesix announces the closing of a $30 million term loan.
BOULDER, Colo.--(BUSINESS WIRE)--Biodesix releases fourth quarter and full year 2020 results
BOULDER, Colo.--(BUSINESS WIRE)-- #BDSX--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial re...
BOULDER, Colo.--(BUSINESS WIRE)-- #BDSX--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that The Healthcare Technology Re...
BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the company has partnered with Chica...
BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that management will participate in two u...
BOULDER, Co.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced a publication describing the development of...
Scott Hutton of Biodesix Selected as USA Chief Executive Officer of the Year by CEO Monthly Magazine
BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that Chief Executive Officer Scott Hutton...
BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that three abstracts from multiple clinic...
NEW YORK & BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX) today announced an agreement with HiberCell, a biotechnology company developing novel therapeutics for cancer relapse and metast...
The IPO market is taking a break during the shortened Thanksgiving week, with just one IPO and two SPACs scheduled to raise $900 million. Russian e-commerce company Ozon Holdings plans to raise $750 mil...
Biodesix has gone public in an offering which was not well-received by the market. Lack of growth and steep losses make investors rightfully cautious based on the conditions as they are today.
About BDSX
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests that provide physicians with timely results to facilitate treatment decisions. It also provides Bio-Rad SARS-CoV-2 ddPCR test, which is designed to detect the presence of infection by ... [Read more...]
| Industry Diagnostics & Research | IPO Date Oct 28, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol BDSX |
Financial Performance
In 2020, Biodesix's revenue was $45.56 million, an increase of 85.55% compared to the previous year's $24.55 million. Losses were -$31.35 million, 2.03% more than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for Biodesix stock is "Strong Buy." The 12-month stock price forecast is 28.00, which is an increase of 96.63% from the latest price.